We continue to maintain a tight control of costs with a laser focus on value and delivery of our core company goals. We are incredibly fortunate to be custodians ... setting a landmark milestone. In ...

(1) During the three months ended September 30, 2023, $10.3 million of income tax benefit was recognized as a result of the release of the valuation allowance previously recorded on our deferred tax ...

Operator Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited earnings conference call. My name is Alex, ...

Operator Good afternoon, everyone, and welcome to Gilead's third quarter 2024 earnings conference call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared ...

From the end of November Market data will no longer be displayed here.